Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn's disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due to their increasing incidence. Recent studies have pointed out genes associated with IBD susceptibility that, together with environmental factors, may contribute to the outcome of the disease. In ulcerative colitis, there are several therapies available, depending on the stage of the disease. Aminosalicylates, corticosteroids, and cyclosporine are used to treat mild, moderate, and severe disease, respectively. In Crohn's disease, drug choices are dependent on both location and behavior of the disease. Nowadays, advances in treatments for IBD have included biological therapies, based mainly on monoclonal antibodies or fusion proteins, such as anti-TNF drugs. Notwithstanding the high cost involved, these biological therapies show a high index of remission, enabling a significant reduction in cases of surgery and hospitalization. Furthermore, migration inhibitors and new cytokine blockers are also a promising alternative for treating patients with IBD. In this review, an analysis of literature data on biological treatments for IBD is approached, with the main focus on therapies based on emerging recombinant biomolecules.

1. Introduction

The role of intestinal milieu in immune homeostasis appears to be of greater significance than it was previously thought. This complex interplay of genetic, microbial, and environmental factors culminates in a sustained activation of the mucosal immune and nonimmune responses. Under normal situations, the intestinal mucosa is in a state of "controlled" inflammation regulated by a delicate balance of Th1, Th17, Th2, Th3, Th9, and Treg cells [1–6].

Inflammatory bowel diseases (IBD) are related to an immunological imbalance of the intestinal mucosa, mainly associated with cells of the adaptive immune system, which respond against self-antigens producing chronic inflammatory conditions in these patients. Ulcerative colitis (UC) and Crohn's disease (CD) are the most studied types of inflammatory bowel diseases, having the highest prevalence in the world population. The pathophysiological mechanisms of IBD are not fully understood, although these diseases have been discovered several decades ago [7–10]. In the present work, we aim to review the current approaches for treating IBD, focusing on the new therapies based on biological molecules.

Correspondence should be addressed to Patricia Ucelli Simioni; psimioni@gmail.com

Received 16 December 2014; Revised 27 February 2015; Accepted 4 March 2015

Academic Editor: Even Fossum

Copyright © 2015 Bruno Rafael Ramos de Mattos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Inflammatory Bowel Disease

It is widely known that the number of bacteria in the gastrointestinal tract is about 10 times higher when compared to eukaryotic cells in the body. Also, the normal enteric bacterial flora is a complex ecosystem of approximately 300–500 bacterial species [11, 12]. Moreover, the balance of the innate and adaptive immunity is critical for this microenvironment homeostasis. In this sense, the immune system has the important role of promoting immune tolerance, thereby avoiding the specific immune response against the large mass of commensal bacteria. The local immunity in intestinal mucosa is basically ensured by gut associated lymphoid tissue (GALT), constituted by Peyer’s patches, lymphoid follicles, and mesenteric lymph nodes [13]. Along with cellular, environmental, and genetic factors, deregulation of immune responses in the intestinal mucosa has been associated with the etiology of IBD. Alterations in the cytokine production of IL-9 in experimental and human ulcerative colitis by regulating intestinal epithelial cells. 

It is also important to report that environmental factors can play a significant role in the development of IBD, although this relationship is poorly understood. Particularly, there are several evidences that tobacco could have an important role in triggering this type of intestinal inflammation [36, 37].

2.1. Crohn’s Disease. Crohn’s disease, one of the most frequent forms of inflammatory disease worldwide, is characterized by the formation of strictures, fistulas, ulcers, and granulomas in the mucosa. Although the CD’s gastrointestinal manifestation can primarily affect the terminal ileum region, it can also compromise any region from the mouth to the rectum of affected patient. The clinical manifestations of CD can include diarrhea or bloody diarrhea, malnutrition, abdominal pain, and weight loss. Extraitestinal findings, for instance, arthropathy or skin disorders, rarely occur. However, manifestations on skin, muscle, or bone of metastatic Crohn’s disease can actually lead to recognition of occult intestinal disease [80–82]. In general, CD has a genetic background and the first-degree relatives of affected individuals have a fivefold greater risk of developing the disease [83, 84].

The localized release of certain cytokines, such as IL-12, IL-17, TNF-α, and IFN-γ, has been implicated in the chronic intestinal inflammation observed in CD patients [51, 85]. The production of IL-12 and IL-18 by antigen-presenting cells (APC) and macrophages generates a polarized differentiation towards Th1 lymphocyte, leading to an increased release of proinflammatory cytokines, including TNF-α and IFN-γ. Additionally, Th1 cytokines stimulate the antigen-presenting cells to secrete a wider spectrum of inflammatory cytokines such as IL-1, IL-6, IL-8, IL-12, and IL-18, resulting in a self-sustained cycle [86].

2.2. Ulcerative Colitis. Ulcerative colitis is another form of IBD characterized by superficial ulcerations, granularity, and a vascular pattern. In contrast with the inflammation found in CD—transmural and being able to occur throughout the entire gastrointestinal tract—inflammation in UC is limited to the mucosal layer of the colon [87, 88]. Although Montreal classification—a system to classify IBD phenotypes including UC—is widely used, data on its reliability are very limited due to the great variety of clinical presentations of UC [88]. In general, the clinical manifestation of UC can include release of blood and mucus, petechial hemorrhage, and granulation...
tissue, among others. However, in periods of remission, the mucosa may have normal appearance. In most severe forms of the disease, the intestine can get distended, presenting deep ulceration and possibly intestinal perforation [87, 89].

In UC, there is a substantial increase in the secretion of IL-13, the main interleukin responsible for the inflammation and chronicity of this condition [87]. Despite the Th1 involvement, UC patients also present a Th2 response with increased secretion of IL-4, IL-5, and IL-9 [3, 5]. It has been suggested that the expression of the PU.1 transcription factor, a regulator of cellular communication, and the production of IL-9 by effector’s Th9 cells block the proliferation of intestinal epithelial cells and regulate the expression of several tight-junction proteins. Together, these aspects favor the translocation of specific bacterial species with subsequent activation of immune cells and mucosal inflammation in experimental and human UC [3]. As in CD, Th17-related cytokines are also increased in UC [34, 90].

3. Treatments for IBD

In order to better illustrate the relevance of each of the different IBD treatments, Table 1 compares different forms of treatment, mechanisms of action, patterns, and adverse effects of each form of therapy.

3.1. Classical Treatments for IBD. In ulcerative colitis, treatment decision is dependent on the stage of the disease: patients with mild manifestations are usually treated with aminosalicylates, whereas corticosteroids are prescribed for those with moderate disease and cyclosporine is given to patients with severe disease. In Crohn’s disease, decisions about drug therapy are dependent on both location and behavior of the disease. Despite that, the medication in CD usually includes aminosalicylates and antibiotics to treat mild mucosal disease, corticosteroids to moderate disease, and biological molecules to treat fistulizing disease. Also, aminosalicylates, azathioprine, mercaptopurine, methotrexate, metronidazole, and associations can be used as maintenance therapies [38, 39, 42, 80, 91–94]. Notwithstanding their reduced cost, these drugs can generate several side effects. Moreover, these therapies do not achieve clinical remission and they can lead to the onset of other conditions such as renal impairment [39, 49, 50].

At the same time the classical treatments are widely used, new therapies are under development in the attempt of improving the patient’s life quality. The new therapies aim to reduce the side effects and to treat patients who do not respond satisfactorily to conventional therapies [51, 52, 74, 95, 96].

Other therapeutic strategies, not covered in this review, are in very early evaluation. These involve the manipulation of the microbiome using antibiotics, probiotics, prebiotics, diet, and fecal microbiota transplantation [93, 97, 98].

3.2. Biological Therapies. The application of biological therapy for the treatment of inflammatory diseases can be associated with some studies that identified the proinflammatory cytokines present in the gut lamina propria of the IBD patients. These cytokines, in particular TNF-α, play a crucial role in the maintenance of chronic inflammation of the intestinal mucosa [53, 54]. Among the biological molecules, the use of monoclonal antibodies specific against TNF-α, cytokine related to the establishment of IBD, seems to be a relevant alternative. These antibodies may activate various mechanisms involved in the immune response, such as induction of apoptosis as well as the blockage of growth factors for the Th cells, antibody production, and complement activation [99].

Although the treatment of IBD with biological molecules, specifically with monoclonal antibodies, presents high specificity and directed mechanism of action, the high cost of this therapy still represents a barrier to be overcome. For this reason, together with this being a therapy in early stages of development, these drugs are generally used as an alternative for patients that are refractory to corticosteroid and aminosalicylates treatments [55, 100].

Also, long-term therapy with biological molecules can cause immunogenicity by generating anti-drug antibodies. These antibodies can promote acute and delayed infusion reactions and can reduce the duration of the patient response to each infusion or injection [101, 102]. In this sense, there is a potential contribution of the complement system as well as of the formation of immune complexes in the augmentation of immunogenicity [103, 104]. In some patients, immunogenicity is restricted to transient low level of antibodies, presenting no clinical effects. However, patients with high levels of anti-drug antibodies are more likely to present a loss of response by the reduction of drug levels, compromising the long-term therapy [101, 102]. As an alternative, concomitant immunosuppression appears to reduce immunogenicity and improve therapeutic control, even though it can present an increased risk for infection and malignancy [105].

Immunogenicity will depend on structure and origin of biologic agents. Biologicals can be fusion protein or a chimeric, and a humanized, or fully human antibody [106]. Also, the administration route, dosing schedule, and individual characteristics can have a great impact on immunogenicity [104, 106]. It is necessary to determine the optimal treatment regimen in order to minimize the likelihood of anti-drug antibody formation.

3.2.1. Anticytokine Agents. Currently, some anticytokine agents have been showing relevant results for the treatment of IBD. It is already known that antibodies specific for TNF-α play an important role in maintaining the remission of CD, in both severe and moderate forms of the disease. These molecules were effective in inducing mucosal healing and clinical remission, reducing the cases of hospitalization and surgical procedures in affected individuals [52, 56–58].

The first commercially available anti-TNF molecule was infliximab (IFX), a chimeric monoclonal IgG1 antibody [52, 56–58] formed by a segment of the native mouse protein containing the binding site for the TNF-α and a portion of human immunoglobulin responsible for the effector function of the antibody molecule [25, 54, 59]. With the introduction
Table 1: IBD treatments: drugs in use, mechanisms of action, and side effects.

| Treatment type            | Related drugs                      | Mechanism of action                                                                 | Features                                                                                                           | Potentials adverse effects                                      | References |
|---------------------------|------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|------------|
| Aminosalicylates          | Mesalamine, Olsalazine, Balsalazide, Sulfasalazine | Inhibition of IL-1, TNF-α, and platelet activating factor (PAF), decreased antibody secretion. | Locally immunosuppressive, nonspecific inhibition of cytokines; medium cost.                                          | Headache, dizziness, dyspepsia, epigastric pain, abdominal pain, nausea, vomiting, and diarrhea. | [38–41]   |
| Immunomodulators          | Azathioprin, 6-mercaptopurin, Methotrexate | Blockage of de novo pathway of purine synthesis.                                     | Antiproliferative effects, reduction of inflammation.                                                                | Black, tarry stools, bleeding gums, chest pain, fever, chills, swollen glands, pain, cough, and weakness. | [42–48]   |
| Corticosteroids           | Prednisone, Methylprednisolone, Hydrocortisone, Budesonide | Blockage of phospholipase A2 in the arachidonic acid cascade altering the balance between prostaglandins and leukotrienes; stimulation of apoptosis of lamina propria lymphocytes; suppression of the transcription of cytokines. | High immunosuppression, risk of potential infections, adverse effects with long periods of use, low cost.          | Abdominal or stomach pain, chest pain, chills, cough, dizziness, fainting, headache, itching, muscle pain, nasal congestion, nausea, sneezing, weakness, vomiting, bloody urine, cracks in the skin, diarrhea, pain, fever, abscess, back or side pain, bone or joint pain, constipation, falls, facial edema, general feeling of illness, hernia, irregular heartbeat, unusual bleeding, weight loss, increased risk of reactivation of latent tuberculosis, and increased risk for developing infections and lymphoma. | [49, 50]   |
| Biologicals: anti-cytokine drugs | Infliximab, Adalimumab, Certolizumab-pegol, Golimumab, Ustekinumab (phase 3 trial) | Induction of apoptosis in proinflammatory cells; binding specifically to TNF-α, blockage of the interaction the receptor. | Specific inhibition of cytokine, immunosuppression, high cost, advanced technology required.                         | Nasopharyngitis, headache and abdominal pain, increased risk of infections, serious infections, and progressive multifocal leukoencephalopathy (natalizumab). | [24, 51–73]|
| Biologicals: anti-cell adhesion molecule | Vedolizumab, Natalizumab | Inhibition of migration.                                                              | Specific inhibition of cell adhesion molecules high cost, advanced technology required.                             |                                                                  | [63, 74–79]|

of IFX in market there was a considerable increase of clinical remission in CD and UC patients. In fact, IFX is currently the approved biologic agent for the treatment of inflammatory and fistulizing Crohn's disease and UC in several countries [52, 56, 57].

In order to treat nonresponsive patients to IFX, adalimumab (ADA), a fully human IgG1 monoclonal antibody, has emerged as an alternative molecule [58]. ADA is the first biotechnological product that is produced by using phage display technology approved by US Food and Drug Administration (FDA). Administration of ADA is indicated for individuals with CD in the moderate and severe forms, also showing positive results for the treatment of UC [58, 60]. The ADA induces apoptosis of proinflammatory cells.
by specifically binding to TNF-α molecule, leading to the blockage of the interaction of this cytokine with their surface receptors p55 and p75 [58]. Biological therapy with monoclonal antibodies IFX and ADA has been increasingly employed in the treatment of IBD, showing a significant improvement of the patient's clinical condition. In general, 45–70% of IBD cases presented clinical remission after being treated with IFX [43, 61, 107], while patients treated with ADA presented clinical remission near 30–60% [55, 61, 108]. However, the treatment with these molecules involves several risks and generates side effects. Renal complications, infusion reaction, delayed hypersensitivity-like reaction, new onset of autoimmunity (with rare cases of drug-induced lupus and new-onset demyelination) and opportunistic infections are some examples of complications resulting from the immunosuppression induced by biological therapy [25, 53, 54, 59, 62]. The fact that these drugs have been recently approved for clinical practice explains why their side effects are not thoroughly known. Because of that, more studies should be conducted in order to fully understand the mechanisms and the consequences of the use of these drugs. Furthermore, these anti-TNF agents did not present relevant effects in all treated patients, indicating another aspect worth investigating [55, 61, 109–111].

In this context, other anti-TNF biologic agents have emerged, including CDP 571, etanercept, and oncept. These humanized or fully human anti-TNF biotechnological agents are theoretically less immunogenic than the chimeric IFX. However, biopharmaceuticals such as etanercept (TNF inhibitor), oncept (recombinant TNF p55 receptor monomer), and CDP571 (recombinant humanized MAb against TNF-α) were not effective for active Crohn's disease [63, 112, 113].

Cetorilizumab pegol (CDP 870), a pegylated and fully humanized monoclonal antibody fragment, is an anti-TNF agent that has recently been approved by FDA for CD treatment with sustained remission [114–116]. Studies show that this drug seems to be more effective and less immunogenic than IFX and ADA [63, 64, 117]. Additionally, golimumab, a human IgG1 TNF-α antagonist monoclonal antibody, also showed significant results in inducing and maintaining remission in CD and UC patients, with a rate of adverse events similar to the placebo [63, 65, 118].

3.2.2. Leukocyte Migration and Signaling Inhibitors. Since the application of biological drugs for treating IBD is a novel approach, there are several new biologic agents that have been recently approved or included in clinical trials or are under evaluation for determining their clinical efficacy and safety profile.

Currently, therapies that manipulate leukocyte adhesion, costimulatory signaling and cytokine receptors are being evaluated as potential treatments for IBD. These alternative treatments emerged when it was observed that some of the patients under current biologic therapies with anti-TNF-α agents were primarily nonresponders or experience a loss of response, intolerance, or even presented side effects [63, 75, 119–122].

Lymphocyte-endothelial interactions, mediated by adhesion molecules, are important in leukocyte migration and recruitment to sites of inflammation. The selective blockage of these adhesion molecules is a new and promising approach to treat CD. Recently approved by FDA, anti-α4 integrin monoclonal antibodies, specifically natalizumab and vedolizumab, were effective in the treatment of moderately to severely active CD (natalizumab and vedolizumab) and for UC (vedolizumab) patients [10, 63, 123]. The blockage of the T cell migration into the intestine by using anti-α4β7 antibody vedolizumab, approved to treat adult patients, resulted in a selective barrier for the trafficking of CD4+CD45RO+ T cells. It also reduced the UC clinical score, presenting a successful remission in 33% to 50% of cases [74, 76, 124].

Meanwhile, clinical efficacy of some therapeutic agents, such as inhibitors of leukocyte trafficking, including allicaforsen, an oligodeoxynucleotide that inhibits intercellular adhesion molecule 1 (ICAM-1) expression, are still under evaluation [123, 125–127]. Among the new drugs being tested, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12/23, approved to use in patients with moderate or severe psoriasis and psoriatic arthritis, was able to induce clinical response in patients with moderate-to-severe CD, especially in those previously treated with IFX [51, 66]. Etrolizumab, a humanized monoclonal antibody that selectively binds to the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, was well tolerated in moderate to severe UC on phase II studies [128, 129]. Additionally, tofacitinib, a small molecule targeting Janus-activated kinase (JAK), was shown to particularly inhibit JAK1 and JAK3, also interfering with several cytokine receptors. However, there are no relevant clinical data related to this molecule [130].

Since one of the most important mechanisms in establishing gastrointestinal inflammatory conditions is the activation of different populations of T cells, the balance among effectors and regulatory populations is crucial for driving the immune response in GALT [131]. In this way, costimulatory signaling of T cell activation has been investigated as a potential target to block unwanted and deleterious inflammatory response. One of these targets is the CTLA-4 molecule, expressed on the surface of T cells, which selectively competes with CD28 molecule for binding to CD80 and CD86 molecules present on APCs. Besides that, it was recently demonstrated that both T regulatory and T conventional cells exert a suppressive function on the externalization of CTLA-4 protein [132]. Thus, new clinical approaches have used the biological molecule abatacept, a fusion protein composed of the Fc portion of IgG together with the CTLA4 molecule (CTLA4-Ig), to treat different inflammatory disorders such as psoriatic arthitis, type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus. However, a phase III trial in moderate-to-severe CD and UC showed no therapeutic benefits with the use of the abatacept, indicating that blocking the T cell activation possibly compromises the activation of important regulatory T cells subsets in IBD patients [133].
3.2.3. Biological Drug Dosage. Nowadays, five biologic agents are approved by FDA for the treatment of IBD: adalimumab, infliximab, golimumab, certolizumab pegol, and vedolizumab. In order to reach an effective disease remission of IBD patients, IFX standard dosage for UC and CD is usually 5 mg/kg by intravenous infusion at weeks 0, 2, and 6, followed by a maintenance regimen every 8 weeks. However, some data shows that the dosage of 10 mg/kg seems to maintain the remission for a longer period [134–137]. On the other hand, ADA has shown to be effective to UC and CD by the subcutaneous administration with an initial dose of 160 milligrams, a second dose two weeks later of 80 mg, and a maintenance dose of 40 mg every other week, although it has also been shown that there is a dose-dependent effectiveness related to this drug [138–140].

In patients with moderate to severe CD, subcutaneous administration of certolizumab pegol on subcutaneous doses of 400 mg once every 4 weeks was effective as induction and maintenance therapy. In case of lack of response, it should be given every 2 weeks [141]. The recommended golimumab initial regimen for the treatment of UC is a 200 mg subcutaneous dose at week 0 followed by 100 mg at week 2. The maintenance therapy is 100 mg every 4 weeks [67]. Vedolizumab was recently approved by FDA for the treatment of adults with moderately to severely active UC and CD. Dose regimen is 300 mg infused intravenously at 0, 2, and 6 weeks and the maintenance therapy at every 8 weeks thereafter [74].

Despite the fact that there are no sufficient comparative trial data available between infliximab, adalimumab, and certolizumab pegol, they are considered as having comparable efficacy, especially when the maintenance of remission is taking into consideration [68, 137]. An advantage of ADA, golimumab, and certolizumab in comparison with IFX and vedolizumab is that they can be administered by a subcutaneous injection. It is important to mention that patient’s history, drug regimen, and drug efficacy create a singular scenario that should be taken into account before choosing the appropriate therapy.

3.2.4. Biosimilars. Additionally, it is important to mention that infliximab’s patent has already expired in many countries (e.g., Brazil, Argentina, Canada, South Korea, and some Eastern Europe countries) and is about to in USA and in Western Europe countries, opening the opportunities for biosimilar drugs to reach the market. Nowadays, IFX-biosimilars are already used in some countries for the treatment of IBD and present a significant reduction in costs.

Biosimilars present the same amino acid sequence and a highly similar glycosylation pattern when compared with the original product. Accordingly, biosimilars represent a future tendency and a promising new option for IBD patients with the main advantage of being less expensive, which may affect the availability of the biological treatment for patients around the world. However, concerns about the efficacy, safety, and immunogenicity of biosimilars still exists [142, 143].

4. Final Considerations

Gastrointestinal immune disorders are most likely facilitated by defects in the intestinal epithelial barrier and in the mucosal immune system, resulting in an active inflammation and tissue destruction. The mucosal immune system is essential for the establishment and controlling of the intestinal inflammation and injury, with cytokines playing a central role in modulating IBD. Therefore, using specific inhibitors or blockers targeting cytokines and chemokines may be a strategic move for treating IBD. Essentially, approved biological molecules for commercial use act as specific inhibitors of inflammatory cytokines related to autoimmune diseases. Among approved TNF blockers, IFX and ADA are the most commonly used biological drugs for the treatment of IBD. Despite the fact that half of the patients treated with these biological molecules have shown clinical remission and its clinical benefits seemed to outweigh the risks involved, there is a growing concern regarding the development of immunogenicity against the biologics, since some patients may develop anti-drug antibodies.

Albeit many studies are still ongoing with the goal of using biological therapy, the effective cost of its production is very elevated in comparison with other drugs, which might make this a hard to implement treatment. Furthermore, treatment with biologicals must be defined carefully, since several drugs need further preclinical and clinical studies prior for their use to be considered as a first option treatment. In this sense, more controlled clinical trials are currently being conducted, exploring the safety and efficacy of old and new biologic agents. Regardless, the most recently engineered biological drugs will certainly open a fresh and exciting perspective on the development and improvement of therapies for IBD.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors would like to thank Marta Baracho, Silvia Mansur Scaglusi, Marcelo Neves, and Luiz Antonio Aparecido (FAM) for suggestions. This work was supported by Grant no. 2013/20258-2 and fellowships nos. 2014/08591-0, 2014/08619-2, and 2014/16701-0, São Paulo Research Foundation (FAPESP).

References

[1] M. F. Neurath and G. Schürmann, “Immunopathogenesis of inflammatory bowel diseases,” Chirurg, vol. 71, no. 1, pp. 30–40, 2000.
[2] M. F. Neurath, “Cytokines in inflammatory bowel disease,” Nature Reviews Immunology, vol. 14, no. 5, pp. 329–342, 2014.
[3] K. Gerlach, Y. Hwang, A. Nikolaev et al., “TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells,” Nature Immunology, vol. 15, pp. 676–686, 2014.
[40] T. P. van Staa, T. Card, R. F. Logan, and H. G. M. Leufkens, "5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study," *Gut*, vol. 54, no. 11, pp. 1573–1578, 2005.

[41] M. P. Leighton, C. Lam, S. Mehta, and R. C. Spiller, "Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial," *Trials*, vol. 14, no. 1, article 10, 2013.

[42] G. B. Porro, A. Cassinotti, E. Ferrara, G. Maconi, and S. Ardizzone, "Review article: the management of steroid dependency in ulcerative colitis," *Alimentary Pharmacology & Therapeutics*, vol. 26, no. 6, pp. 779–794, 2007.

[43] B. G. Feagan, J. W. D. McDonald, R. Panaccione et al., "Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease," *Gastroenterology*, vol. 146, no. 3, pp. 681.e1–688.e1, 2014.

[44] S. Ardizzone, G. Maconi, G. M. Sampietro et al., "Azathioprine and mesalazine for prevention of relapse after conservative surgery for Crohn's disease," *Gastroenterology*, vol. 127, no. 3, pp. 730–740, 2004.

[45] J. S. Maltzman and G. A. Koretzky, "Azathioprine: old drug, new actions," *Journal ofClinicalInvestigation*, vol. 111, no. 8, pp. 1122–1124, 2003.

[46] S. Ardizzone, G. Maconi, A. Russo, V. Imbesi, E. Colombo, and G. B. Porro, "Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis," *Gut*, vol. 55, no. 1, pp. 47–53, 2006.

[47] J. Cox, T. K. Daneshmend, C. J. Hawkey, R. F. A. Logan, and R. P. Walt, "Devastating diarrhoea caused by azathioprine: management difficulty in inflammatory bowel disease," *Gut*, vol. 29, no. 5, pp. 686–688, 1988.

[48] T. R. Ziegler, C. Fernández-Estivariz, L. H. Gu, M. W. Fried, and L. M. Leader, "Severe villus atrophy and chronic malabsorption induced by azathioprine," *Gastroenterology*, vol. 124, no. 7, pp. 1950–1957, 2003.

[49] C. Reichel, J. Streit, K. Ott, and S. Wunsch, "Appropriateness of Crohn's disease therapy in gastroenterological rehabilitation," *Digestion*, vol. 82, no. 4, pp. 239–245, 2010.

[50] F. Leonard, H. Ali, E.-M. Collnot et al., "Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model," *Altx*, vol. 29, no. 3, pp. 275–285, 2012.

[51] W. J. Sandborn, B. G. Feagan, R. N. Fedorak et al., "A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease," *Gastroenterology*, vol. 135, no. 4, pp. 1130–1141, 2008.

[52] B. E. Sands, W. J. Tremaine, W. J. Sandborn et al., "Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study," *Inflammatory Bowel Diseases*, vol. 7, no. 2, pp. 83–88, 2001, http://www.ncbi.nlm.nih.gov/pubmed/11383595.

[53] S. R. Targan, S. B. Hanauer, S. J. H. van Deventer et al., "A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease," *The New England Journal of Medicine*, vol. 337, no. 15, pp. 1029–1036, 1997.

[54] D. H. Present, P. Rutgeerts, S. Targan et al., "Infliximab for the treatment of fistulas in patients with Crohn’s disease," *The New England Journal of Medicine*, vol. 340, no. 18, pp. 1398–1405, 1999.

[55] P. G. Kotze, V. R. Abou-Rejaile, L. U. Euema et al., "Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study," *Arquivos de Gastroenterologia*, vol. 51, no. 1, pp. 39–45, 2014.

[56] H. M. van Dullemen, S. J. H. van Deventer, D. W. Hommes et al., "Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)," *Gastroenterology*, vol. 109, no. 1, pp. 129–135, 1995.

[57] A. Lopez, V. Billioud, C. Peyrin-Biroulet, and L. Peyrin-Biroulet, "Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review," *Inflammatory Bowel Diseases*, vol. 19, no. 7, pp. 1528–1533, 2013.

[58] R. Panaccione, E. V. Loftus Jr., D. Binion et al., "Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the adalimumab in Canadian subjects with moderate to severe Crohn's disease (ACCESS) trial," *Canadian Journal of Gastroenterology*, vol. 25, no. 8, pp. 419–425, 2011.

[59] S. B. Hanauer, "Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies," *Reviews in Gastroenterological Disorders*, vol. 4, supplement 3, pp. S18–S24, 2004, http://www.ncbi.nlm.nih.gov/pubmed/15580149.

[60] W. J. Sandborn, G. van Assche, W. Reinisch et al., "Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis," *Gastroenterology*, vol. 142, no. 2, pp. 257.e3–265.e3, 2012.

[61] M. R. Hardt, P. G. Kotze, F. E. Teixeira et al., "Epidemiological profile of 175 patients with Crohn's disease submitted to biological therapy," *Journal of Coloproctology*, vol. 32, no. 4, pp. 395–401, 2012.

[62] X. Robin, H. Marotte, M. Rinaudo et al., "Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases," *Clinical Gastroenterology and Hepatology*, vol. 12, no. 1, pp. 80–82, 2014.

[63] S. Mozaffari, S. Nikfar, A. H. Abdolghaffari, and M. Abdollahi, "New biologic therapeutics for ulcerative colitis and Crohn's disease," *Expert Opinion on Biological Therapy*, vol. 14, no. 5, pp. 583–600, 2014.

[64] W. J. Sandborn, M. T. Abreu, G. D’Haens et al., "Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab," *Clinical Gastroenterology and Hepatology*, vol. 8, no. 8, pp. 688.e2–695.e2, 2010.

[65] S. Danese, "IBD: golimumab in ulcerative colitis: a ‘ménage à trois’ of drugs," *Nature Reviews Gastroenterology and Hepatology*, vol. 10, no. 9, pp. 511–512, 2013.

[66] W. J. Sandborn, C. Gasink, L.-L. Gao et al., "Ustekinumab induction and maintenance therapy in refractory Crohn's disease," *The New England Journal of Medicine*, vol. 367, no. 16, pp. 1519–1528, 2012.

[67] W. J. Sandborn, B. G. Feagan, C. Marano et al., "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis," *Gastroenterology*, vol. 146, no. 1, pp. 85–95, 2014.

[68] R. Fausel and A. Afzali, "Biologics in the management of ulcerative colitis—comparative safety and efficacy of TNF-α antagonists," *Therapeutics and Clinical Risk Management*, vol. 11, pp. 63–73, 2015.

[69] M. Barreiro-de Acosta, A. Lorenzo, and J. E. Dominguez-Munoz, "Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years," *World Journal of Gastroenterology*, vol. 15, pp. 3814–3816, 2009.

[70] K. S. Nanda, A. S. Cheifetz, and A. C. Moss, "Impact of antibodies to infliximab on clinical outcomes and serum infliximab
levels in patients with inflammatory bowel disease (IBD): a meta-analysis,” The American Journal of Gastroenterology, vol. 108, no. 1, pp. 40–47, 2013.

[71] C. Abreu, F. Magro, J. Santos-Antunes et al., “Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population,” Journal of Crohn’s and Colitis, vol. 7, no. 10, pp. e486–e492, 2013.

[72] J. M. F. Chebli, P. D. Gaburri, L. A. Chebli et al., “A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy,” Medical Science Monitor, vol. 20, pp. 487–498, 2014.

[73] T. S. Shim, “Diagnosis and treatment of latent tuberculosis infection in patients with inflammatory bowel diseases due to initiation of anti-tumor necrosis factor therapy,” Intestinal Research, vol. 12, no. 1, pp. 12–19, 2014.

[74] B. G. Feagan, P. Rutgeerts, B. E. Sands et al., “Vedolizumab as induction and maintenance therapy for ulcerative colitis,” The New England Journal of Medicine, vol. 369, no. 8, pp. 699–710, 2013.

[75] M. Bosani, S. Ardizzone, and G. B. Porro, “Biologic targeting in the treatment of inflammatory bowel diseases,” Biologics, vol. 3, Article ID 2726060, pp. 77–97, 2009.

[76] A. Parikh, T. Leach, T. Wyant et al., “Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study,” Inflammatory Bowel Diseases, vol. 18, no. 8, pp. 1470–1479, 2012.

[77] S. Danese and J. Panés, “Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases,” Gastroenterology, vol. 147, no. 5, pp. 981–989, 2014.

[78] W. J. Sandborn, B. G. Feagan, P. Rutgeerts et al., “Vedolizumab as induction and maintenance therapy for Crohn’s disease,” The New England Journal of Medicine, vol. 369, no. 8, pp. 711–721, 2013.

[79] F. Rossi, S. D. Newsome, and R. Viscidi, “Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients,” Molecular and Cellular Probes, vol. 29, no. 1, pp. 54–62, 2015.

[80] P. A. Rufo and A. Bousvaros, “Current therapy of inflammatory bowel disease in children,” Pediatric Drugs, vol. 8, no. 5, pp. 279–302, 2006.

[81] E. Zold, A. Nagy, K. Devenyi, M. Zeher, and Z. Barta, “Successful use of adalimumab for treating fistulizing Crohn’s disease with pyoderma gangrenosum: two birds with one stone,” World Journal of Gastroenterology, vol. 15, no. 18, pp. 2293–2295, 2009.

[82] H. J. Freeman, “Natural history and long-term clinical course of Crohn’s disease,” World Journal of Gastroenterology, vol. 20, pp. 31–36, 2014.

[83] G. Guariso, M. Gasparetto, L. Visonnà Dalla Pozza et al., “Inflammatory bowel disease developing in paediatric and adult age,” Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no. 6, pp. 698–707, 2010.

[84] M. W. Laass, D. Roggenbuck, and K. Conrad, “Diagnosis and classification of Crohn’s disease,” Autoimmunity Reviews, vol. 13, no. 4–5, pp. 467–471, 2014.

[85] I. R. Williams, “Chemokine receptors and leukocyte trafficking in the mucosal immune system,” Immunologic Research, vol. 29, no. 1–3, pp. 283–291, 2004.

[86] S. Plevy, “The immunology of inflammatory bowel disease,” Gastroenterology Clinics of North America, vol. 31, no. 1, pp. 77–92, 2002.

[87] M. S. Silverberg, J. Satsangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” Canadian Journal of Gastroenterology, vol. 19, supplement A, pp. 5A–36A, 2005, http://www.ncbi.nlm.nih.gov/pubmed/16151544.

[88] L. M. Spekhorst, M. C. Visschedijk, R. Alberts et al., “Performance of the Montreal classification for inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 20, pp. 15374–15381, 2014.

[89] R. W. Sherbaniuk, “Ulcerative colitis: disease patterns and medical management,” Canadian Medical Association Journal, vol. 91, pp. 30–36, 1964.

[90] T. Kobayashi, S. Okamoto, T. Hisamatsu et al., “IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease,” Gut, vol. 57, no. 12, pp. 1682–1689, 2008.

[91] A. Cassinotti, A. Massari, E. Ferrara et al., “New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature,” European Journal of Clinical Pharmacology, vol. 63, no. 9, pp. 875–878, 2007.

[92] J. W. D. McDonald, Y. Wang, D. J. Tsoulis, J. K. MacDonald, and B. G. Feagan, “Methotrexate for induction of remission in refractory Crohn's disease,” Cochrane Database of Systematic Reviews, vol. 8, Article ID CD003459, 2014.

[93] G. R. D’Haens, R. B. Sartor, M. S. Silverberg, J. Petersson, and P. Rutgeerts, “Future directions in inflammatory bowel disease management,” Journal of Crohn’s and Colitis, vol. 8, pp. 726–734, 2014.

[94] A. Bousvaros, “Use of immunomodulators and biologic therapies in children with inflammatory bowel disease,” Expert Review of Clinical Immunology, vol. 6, no. 4, pp. 659–666, 2010.

[95] G. Monteleone, R. Caruso, and F. Pallone, “Targets for new immunomodulation strategies in inflammatory bowel disease,” Autoimmunity Reviews, vol. 13, no. 1, pp. 11–14, 2014.

[96] W. Reinsch, W. de Villiers, L. Bene et al., “Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study,” Inflammatory Bowel Diseases, vol. 16, no. 2, pp. 233–242, 2010.

[97] M.-I. Torres and A. Rios, “Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy,” World Journal of Gastroenterology, vol. 14, no. 13, pp. 1972–1980, 2008.

[98] P. C. Calder and S. Kew, “The immune system: a target for functional foods?” The British Journal of Nutrition, vol. 88, supplement 2, pp. S165–S176, 2002.

[99] L. Castilho, A. Moraes, E. Augusto, and M. Butler, Eds., Animal Cell Technology: From Biopharmaceuticals to Gene Therapy, Taylor & Francis, 1stedition, 2008.

[100] J. Dretzke, R. Edlin, J. Round et al., “A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for crohn’s disease,” Health Technology Assessment, vol. 15, no. 6, pp. 1–244, 2011.

[101] S. B. Hanauer, “Risks and benefits of combining immunomodulators and biological agents in inflammatory bowel disease: is the synergy worth the risk?” Gut, vol. 56, no. 9, pp. 1181–1183, 2007.
Mediators of Inflammation in inflammatory bowel disease,” *Gastroenterology*, vol. 143, no. 1, pp. 13–17, 2012.

[134] P. Rutgeerts, G. van Assche, and S. Vermeire, “Review article: infliximab therapy for inflammatory bowel disease—seven years on,” *Alimentary Pharmacology and Therapeutics*, vol. 23, no. 4, pp. 451–463, 2006.

[135] S. Bandzar, S. Gupta, and M. O. Platt, “Crohn’s disease: a review of treatment options and current research,” *Cellular Immunology*, vol. 286, no. 1-2, pp. 45–52, 2013.

[136] A. C. Moss, V. Brinks, and J. F. Carpenter, “Review article: immunogenicity of anti-TNF biologics in IBD—the role of patient, product and prescriber factors,” *Alimentary Pharmacology & Therapeutics*, vol. 38, no. 10, pp. 1188–1197, 2013.

[137] P. Rutgeerts, S. Vermeire, and G. van Assche, “Biological therapies for inflammatory bowel diseases,” *Gastroenterology*, vol. 136, no. 4, pp. 1182–1197, 2009.

[138] Press Announcements, FDA approves Humira to treat ulcerative colitis, 2015, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm.

[139] A. O’Connor and A. C. Moss, “Current and emerging maintenance therapies for ulcerative colitis,” *Expert Review of Gastroenterology and Hepatology*, vol. 8, no. 4, pp. 359–368, 2014.

[140] C. B. Burness and G. M. Keating, “Adalimumab: a review of its use in the treatment of patients with ulcerative colitis,” *BioDrugs*, vol. 27, no. 3, pp. 247–262, 2013.

[141] S. K. A. Blick and M. P. Curran, “Certolizumab pegol: in Crohn’s disease,” *BioDrugs*, vol. 21, no. 3, pp. 195–203, 2007.

[142] S. Danese and F. Gomollon, “ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD),” *Journal of Crohn’s and Colitis*, vol. 7, no. 7, pp. 586–589, 2013.

[143] T. Hlavaty and J. Letkovsky, “Biosimilars in the therapy of inflammatory bowel diseases,” *European Journal of Gastroenterology and Hepatology*, vol. 26, no. 6, pp. 581–587, 2014.